Posted by Michael Wonder on 13 Mar 2026
Novartis Cosentyx receives FDA approval for paediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
13 March 2026 - Novartis announced today that Cosentyx (secukinumab) received US FDA approval for treating paediatric patients 12 years and older with moderate to severe hidradenitis suppurativa, making it the only IL-17A inhibitor for this population.
The approval of a distinct biologic option for paediatric patients living with hidradenitis suppurativa allows treatment to be tailored to the individual and establishes Cosentyx as a meaningful addition to the treatment landscape.
